Determination of the human cytochrome P450s involved in the metabolism of 2n-propylquinoline

Xenobiotica

Volumn 33, Issue 4, 2003, Pages 341-355

  Belliard, A M ^a,c   Baune, B ^c   Fakhfakh, M ^b   Hocquemiller, R ^a,b   Farinotti, R ^a,c  

^a Laboratoire de Pharmacie Clinique   (France)

^b UNIVERSITÉ PARIS SUD   (France)

^c Serv Pharm Clin des Biomateriaux   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 N PROPYLQUINOLINE; CYTOCHROME P450; EPOXIDE HYDROLASE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; BIOTRANSFORMATION; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LYMPHOBLAST; MICHAELIS CONSTANT; VISCERAL LEISHMANIASIS;

ADULT; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; EPOXIDE HYDROLASES; FEMALE; HUMANS; ISOENZYMES; KINETICS; LYMPHOCYTES; MALE; MICROSOMES, LIVER; NADP; OXIDATION-REDUCTION; QUINOLINES;

EID: 0038171262     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825031000065188     Document Type: Article

References (35)

1. ARMSTRONG, R. N., 1999, Kinetic and chemical mechanism of epoxide hydrolase. Drug Metabolism and Disposition Reviews, 31, 71-86.
2. BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as tool for investigation of metabolic reaction catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 227, 321-332.
3. BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1999, Role of cytochrome P-450 2C9 in irbesartan oxidation by human liver microsomes. Drug Metabolism and Disposition, 27, 288-296.
4. BOYD, D. R., BUSHMAN, D. R., DAVIES, R. J. H., DORRITY, M. R. J., HAMILTON, L., JERINA, D. M., LEVIN, W., MCCULLOUGH, J. J., MCMORDIE, A. S., MALONE, J. F. and POTER, H. P., 1991, Absolute configurations of the arene oxide, trans-dihydrodiol and cis-dihydrodiol products resulting from metabolism of quinoline at the 5,6-bond. Tetrahedron Letters, 32, 2963-2966.
5. BRADFORD, M. M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.
6. CARRIERE, V., BERTHOU, F., BAIRD, S., BELLOC, C., BEAUNE, P. and DE WAZIERS, I., 1996, Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics, 6, 203-211.
7. CHALMERS, D. and BROWN, S., 1987, Epoxide hydrolase expression in human and rodent established cell lines. Xenobiotica, 17, 71-77.
8. CHING, M. S., BLAKE, C. L., GHABRIAL, H., ELLIS, SW., LENNARD, M. S., TUCKER, G. T. and SMALLWOOD, R. A., 1995, Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochemical and Pharmacology, 50, 833-837.
9. DRAGACCI, S., THOMASSIN, J., MAGADALOU, J., SOUHAILI EL AMRI, H., BOISSEL, P. and SIEST, G., 1987, Properties of human hepatic UDP-glucuronosyl transferases. Relationship to other inducible enzymes in patients with cholestasis. European Journal of Clinical and Pharmacology, 32, 485-491.
10. EAGLING, V. A., TJIA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107-114.
11. FOURNET, A., BARRIOS, A. A., MUNOZ, V., HOCQUEMILLER, R., CAVÉ, A. and BRUNETON, J., 1993, 2 SUBSTITUTED QUINOLINE ALKALOIDS AS POTENTIAL ANTILEISHMANIAL DRUGS. Antimicrobial Agents and Chemotherapy, 37, 859-863.
12. FOURNET, A., BARRIOS, A., MUNOZ, V., HOCQUEMILLER, R., ROBLOT, F., CAVÉ, A., RICHOMME, P. and BRUNETON, J., 1994a, Antiprotozoal activity of quinoline alkaloids isolated from Galipea longiflora, a Bolivian plant used as treatment for cutaneous leishmaniasis. Phytotherapy Research, 8, 174-178.
13. FOURNET, A., FERREIRA, M. E., ROJAS DE ARIAS, A., TORRES DE ORTIZ, S., FUENTES, S., NAKAYAMA, H., SCHININI, A. and HOCQUEMILLER, R., 1996, In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrobial Agents and Chemotherapy, 40, 2447-2451.
14. FOURNET, A., GANTIER, J. C., GAUTHERET, A., LEYSALLES, L., MUNOS, M. H., MAYRARGUE, J., MOSKOWITZ, H., CAVÉ, A. and HOCQUEMILLER, R., 1994b, The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. Journal of Antimicrobial Chemotherapy, 33, 537-544.
15. FOURNET, A., MUNOS, V., MANJON, A. M., ANGELO, A., HOCQUEMILLER, R., CORTES, D., CAVÉ, A. and BRUNETON, J., 1998, Activité antiparasitaire d'alcaloïdes bisbenzylisoquinoléiques: Activité in vitro sur des promastigotes de trois souches de leishmania. Journal of Ethnopharmacology, 24, 327-335.
16. GORSKI, J. C., HALL, S. D., JONES, D. R., VANDEN BRADEN, M. and WRIGHTON, SA., 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP 3A) subfamily. Biochemical Pharmacology, 47, 1643-1653.
17. HALL, S. D., GUENGERICH, F. P., BRANCH, R. A. and WILKINSON, G. R., 1987, Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 240, 216-222.
18. IGLARZ, M., BAUNE, B., GANTIER, J. C., HOCQUEMILLER, R. and FARINOTTI, R., 1998, Determination of 2n-propylquinoline in mouse plasma and liver by high-performance liquid chromatography. Journal of Chromatography B, 714, 335-340.
19. KINONEN, T., PASANEN, M., GYNTHER, J., POSO, A., JARVINEN, T., ALHAVA, E. and JUVONEN, R. O., 1995, Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6. British Journal of Pharmacology, 116, 2625-2630.
20. LEEMAN, T. D., TRANSON, C., BONNABRY, P. and DAYER, P., 1993, A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal anti-inflammatory drugs. Drugs Experimental and Clinical Research, 19, 189-195.
21. LIN, J. H. and LU, A. Y., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetic, 35, 361-390.
22. MÄENPÄÄ, J., SIGUSCH, H., RAUNIO, H., SYNGELMA, T., VUORELA, P., VUORELA, H. and PELKONEN, O., 1993, Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochemical Pharmacology, 45, 1035-1042.
23. MAURICE, M., PICHARD, L., DAUJAT, M., FABRE, I., JOYEUX, H., DOMERGUE, J. and MAUREL, P., 1992, Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal, 6, 752-758.
24. MICHALETS, E. L. M., 1998, Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy, 18, 84-112.
25. MINERS, J. O., SMITH, K. J., ROBSON, R. A., MCMANUS, M. E., VERONESE, M. E. and BIRKETT, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes: kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Pharmacology, 37, 1137-1144.
26. MOLTKE, L. L., GREENBLATT, D. J., SCHMIDER, J., WRIGHT, E., HARMATZ, J. S. and SHADER, R. I., 1998, In vitro approaches to predict drug interactions in vivo. Biochemical Pharmacology, 55, 113-122.
27. NAKAJIMA, M., YAMAMOTO, T., NUNOYA, K., YOKOI, T., NAGASHIMA, K., INOUE, K., FUNAE, Y., SHIMADA, N., KAMATAKI, T. and KUROIWA, Y., 1996, Characterization of CYP 2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 1010-1015.
28. ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
29. PASTRAKULJIC, A., TANG, B. K., ROBERTS, E. A. and KALOW, W., 1997, Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochemical Pharmacology, 53, 531-538.
30. RELLING, M. V, AOYAMA, T., GONZALEZ, F. and MEYER, U. A., 1990, Tolbutamide and mephenytoin hydroxylation by human P450 in the CYP 2C subfamily. Journal of Pharmacology and Experimental Therapeutics, 252, 442-447.
31. TANAKA, E., 1998, Clinically important pharmacokinetic drug-drug interactions: role of Cytochrome P450 enzymes. Journal of Clinical Pharmacology and Therapeutics, 23, 403-416.
32. TASSANEEYAKUL, W., BIRKETT, D. J., MCMANUS, M. E., TASSANEEYAKUL, W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. and MINERS, J. O., 1994, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochemical Pharmacology, 47, 1767-1776.
33. TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., GONZALEZ, F. J. and MINERS, J. O., 1993, VALIDATION OF 4NITROPHENOL AS AN in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochemical Pharmacology, 46, 1975-1981.
34. VERONESE, M. E., DOECKE, C. J., MACKENZIE, P. I., MCMANUS, M. E., MINERS, J. O., REES, D. L., GASSER, R., MEYER, U. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal, 289, 533-538.
35. YUN, H. Y., SHIMADA, T. and GUENGERICH, F. P., 1991, Purification and characterization of human liver microsomal cytochrome P-450 2A6. Molecular Pharmacology, 40, 679-685.